The US Food and Drug Administration (FDA) is encouraging the use of gene therapy for HIV in humans and in animal models to fight the virus.
The US Food & Drug Administration is encouraging clinical trials of gene therapies to treat HIV in people and animals.
The approval by the FDA comes a week after the US government cleared a preliminary phase 1 clinical trial of a gene therapy called Crispr-Cas9.
The drug works by targeting a specific gene that is part of HIV.
Gene therapy involves inserting a gene into a person’s cells that will then change the gene.
This gene-therapy approach has already been used in humans for several years, with many researchers finding success in treating HIV patients.
However, the FDA approved a single trial in 2018 to test the gene therapy in human subjects.
This trial was led by researchers at Brigham and Women’s Hospital, the University of Massachusetts and the University at Buffalo.
The study is now in its second phase of clinical trials, but the drug should be available to people and the animal models by 2020.
According to the FDA, the first clinical trial will enroll more than 100 people who will receive the drug in a phase 1 trial in 2020 and will enroll another 100 people in a second phase in 2020.
It will also enroll additional people in Phase 2 trials.
The trial is part, but not the only, of the US drug approval process.
In 2018, the agency approved the first human gene therapy treatment for cancer called CARTYX, but only after a review of more than 6,500 clinical trials and more than 20,000 patients.
The FDA approved CARTyX to treat a type of cancer known as HER2-positive breast cancer, and it is now approved for use in other cancers and other conditions.
This study is one of the first to show that gene therapy can be effective against HIV.
It’s not the first time that gene therapies have been approved for other diseases, however.
In January, the US FDA approved the use in the US for the treatment of lung cancer.
Gene therapies have also been approved in other countries, including China, Japan, India, Brazil, Argentina, Mexico and the United Kingdom.